Ashwagandha: the plant, its constituents and the research
Ashwagandha has become one of the most widely sold plant preparations of the last decade. Behind the name stands a specific botanical species with a long history of use and a body of clinical research that is young, small in scale and concentrated in a few study centres. This article describes the plant, its chemistry, the extracts on the market, what trials report and the safety data that regulators have published.
Botany and names
Withania somnifera (L.) Dunal is a shrub of the nightshade family, Solanaceae, the same family as tomato, potato and belladonna. It grows to between 35 and 150 centimetres, bears greenish bell-shaped flowers and small red berries enclosed in a papery calyx, and tolerates dry, poor soils. The species is native to India, Nepal, Pakistan, the Arabian peninsula and parts of North Africa, and is cultivated commercially above all in the Indian states of Madhya Pradesh and Rajasthan.
The Sanskrit name ashwagandha is usually translated as smell of a horse, a reference to the odour of the fresh root. The species epithet somnifera means sleep-bringing. The plant is also called Indian ginseng, although it has no botanical relationship to Panax ginseng, and winter cherry. The root is the part most used; some extracts also include the leaf.
Constituents
The characteristic compounds are the withanolides, a class of steroidal lactones built on an ergostane skeleton with a lactone ring in the side chain. More than forty have been described from this species. The most studied are:
- Withaferin A: the most reactive member, concentrated in the leaf, carrying an epoxide and an enone group that react readily with protein thiols. Most of the cell-culture literature on this plant concerns this compound.
- Withanolide A and withanolide D: found mainly in the root.
- Withanosides: glycosides of the withanolides, among them sitoindosides.
Alongside these, the root contains alkaloids such as somniferine, tropine and anaferine, as well as steroidal saponins. The withanolide content of root material is low, typically well under one percent, and varies with provenance, harvest time and plant part. Commercial extracts are therefore standardised, usually to between 1.5 and 10 percent total withanolides. Analytical surveys have found that different laboratories measure withanolide content by different methods, so figures on labels are not directly comparable.
Extracts on the market
Most clinical trials use one of a small number of branded extracts, and results obtained with one cannot be transferred to another:
- KSM-66: a water-based root-only extract standardised to at least 5 percent withanolides, used in a large share of the published trials.
- Sensoril: an extract of root and leaf standardised to at least 10 percent withanolides, with a correspondingly different composition, including more withaferin A.
- Shoden: a leaf and root extract standardised to a high withanolide glycoside content, used at lower daily amounts.
- Traditional preparations: churna, the dried powdered root, used in ayurvedic practice, typically in gram amounts and not standardised.
Traditional use
Ashwagandha appears in the classical ayurvedic compendia, including the Charaka Samhita, where it is placed in the rasayana category, a group of preparations traditionally associated with vitality and longevity. It is also used in Unani medicine. Traditional use documents a long history of consumption; it is not evidence of a physiological effect in the modern sense.
Clinical research
Randomised trials on this plant have appeared mainly since 2008. They are reported here with model, participant numbers and the limitations the reviews describe.
- Stress scales and cortisol: a 2012 randomised, double-blind trial in 64 adults in India gave 300 mg of a root extract twice daily over 60 days and reported lower serum cortisol values and lower scores on perceived-stress questionnaires in the extract group than in the placebo group. Several later trials with 50 to 130 participants used similar designs with comparable outcomes. A 2021 systematic review of these trials rated the overall certainty of the evidence as low, pointing to small samples, short duration, concentration in a small number of Indian study centres and frequent funding by extract manufacturers.
- Sleep: trials published between 2019 and 2021 with 60 to 150 participants examined sleep questionnaires such as the Pittsburgh Sleep Quality Index, in some cases alongside actigraphy, over six to twelve weeks at daily amounts of 120 to 600 mg of extract. A 2021 meta-analysis of five such trials reported differences in questionnaire scores against placebo and again noted the small sample sizes and the risk of bias.
- Strength training: a 2015 randomised trial in 57 untrained men combined 300 mg of a root extract twice daily with an eight-week resistance training programme and reported differences in one-repetition maximum values and in arm circumference against training plus placebo. The trial was small and single-centre.
- Endurance measures: trials in athletes have measured maximal oxygen uptake over eight to twelve weeks, reporting differences of varying size in participant groups of 40 to 50.
- Hormone values: trials in men have measured serum testosterone, DHEA-S and semen parameters during extract intake, with participant numbers between 40 and 60 and durations of eight to sixteen weeks. Reviews describe the data as preliminary.
- Thyroid values: a 2018 pilot trial in 50 people with subclinical hypothyroidism measured changes in TSH, T3 and T4 during intake of 600 mg of extract daily over eight weeks. This finding matters mainly because it indicates a possible interaction with thyroid status and thyroid medication.
- Cognitive tests: small trials with 50 to 130 participants have applied memory and attention batteries over eight weeks. The results are heterogeneous and the test instruments differ between trials.
Daily amounts used in these trials lie mostly between 250 and 600 mg of standardised extract, usually divided into two portions. These figures describe what the studies administered.
Safety data, interactions and restrictions
- Reported adverse effects are gastrointestinal complaints, nausea, diarrhoea and drowsiness.
- Since 2019, case series have been published describing liver injury in temporal association with ashwagandha preparations, including a 2020 report of five cases from Iceland and the United States; the cases were mostly reversible after discontinuation. European pharmacovigilance bodies have taken up the question.
- The Danish Technical University published an assessment in 2020 concluding that withanolide intakes from supplements could affect thyroid hormones and sex hormones and could act on the uterus; Denmark subsequently restricted the sale of such products. Several national authorities have since issued their own assessments.
- Use during pregnancy is advised against in the reviews and in traditional sources alike, because of the described action on the uterus. Data during breastfeeding are insufficient.
- Interactions are discussed with sedatives and benzodiazepines, with thyroid medicines, with antidiabetic and antihypertensive medicines, and with immunosuppressants.
- Caution is advised in autoimmune conditions, since constituents have been described as immunomodulating in laboratory models.
- As a member of the nightshade family, the plant may be unsuitable for people with known sensitivity to Solanaceae.
- Anyone taking prescription medicines or living with a chronic condition should discuss the use of such preparations with a physician beforehand.
Regulatory status in the European Union
Ashwagandha root preparations are sold in several member states as food supplements on the basis of a history of consumption before May 1997, which places them outside the novel food authorisation requirement; leaf preparations are assessed differently in some states. National rules diverge: Denmark has restricted marketing, and other authorities have published risk assessments of their own. No health claim for ashwagandha has been authorised under Regulation (EC) No 1924/2006; the related applications are on hold together with the other botanical claims.